1
|
Chiesa S, Beghella Bartoli F, Mazzarella C, Hohaus S, Cannatà M, Catucci F, D'Alò F, Bracci S, Nardangeli A, Martino A, Dinapoli N, Marazzi F, Manfrida S, Gambacorta M, Aristei C, Valentini V, Balducci M. OC-0929 How to manage consolidative radiotherapy after HD methotrexate in PCNSL patients: a phase II study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02709-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Spina V, Pirosa MC, Bruscaggin A, Condoluci A, Pini K, Forestieri G, Zangrilli I, di Trani M, Kurlapski M, Moccia A, Moia R, Bulian P, Annunziata S, Borsatti E, Rodari M, Romanowicz G, Sacchetti GM, Faderl M, Koch R, Piffaretti D, Terzi di Bergamo L, Stasia A, Cittone M, Chauvie S, Stüssi G, Gerber B, Stathis A, Sommer SG, Cavalli F, Zucca E, Gattei V, Zaucha JM, Pinto A, Gaidano G, Carlo‐Stella C, Hohaus S, Ceriani L, Rossi D. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.70_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
3
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
4
|
Spina M, Merli F, Puccini B, Cavallo F, Cabras M, Fabbri A, Angrilli F, Zilioli V, Marino D, Balzarotti M, Ladetto M, Cox M, Petrucci L, Arcari A, Gini G, Chiappella A, Hohaus S, Musuraca G, Merli M, Sartori R, Nassi L, Tani M, Re F, Flenghi L, Molinari A, Kovalchuk S, Bottelli C, Ferrero S, Dessì D, Cencini E, Pennese E, Marcheselli L, Mammi C, Luminari S, Tucci A. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.58_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Spina
- Division of Medical Oncology and Immune-related tumors; National Cancer Institute; Aviano (PN) Italy
| | - F. Merli
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - B. Puccini
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - M.G. Cabras
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - A. Fabbri
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - F. Angrilli
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | - V.R. Zilioli
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - D. Marino
- Medical Oncology 1; Veneto Institute of Oncology IOV IRCCS; Padova Italy
| | - M. Balzarotti
- Department of Medical Oncology and Hematology; Humanitas, Clinical and Research Hospital-IRCCS; Rozzano (MI) Italy
| | - M. Ladetto
- Division of Hematology; A.O. SS Antonio e Biagio and Cesare Arrigo; Alessandria Italy
| | - M.C. Cox
- Hematology Unit; AOU Sant'Andrea; Roma Italy
| | - L. Petrucci
- Institute of Hematology; Dept. of Translational and Precision Medicine “Sapienza”, University of Roma; Roma Italy
| | - A. Arcari
- Haematology Unit; Azienda AUSL; Piacenza Italy
| | - G. Gini
- Division of Haematology; Ospedali Riuniti; Ancona Italy
| | - A. Chiappella
- Division of Hematology; Città della Salute e della Scienza Hospital and University; Torino Italy
| | - S. Hohaus
- Catholic University of the Sacred Heart; University Policlinico Gemelli Foundation, IRCCS; Roma Italy
| | - G. Musuraca
- Department of Hematology; Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori; Meldola (FC) Italy
| | - M. Merli
- Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - R. Sartori
- Hematology Department; Castelfranco Veneto Regional Hospital; Castelfranco Veneto (TV) Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - M. Tani
- Department of Hematology; S. Maria delle Croci Hospital; Ravenna Italy
| | - F. Re
- Hematology and BMT Center; Azienda Ospedaliera, University of Parma; Parma Italy
| | - L. Flenghi
- Hematology; S. Maria della Misericordia Hospital; Perugia Italy
| | - A. Molinari
- Hematology Unit; Infermi Hospital; Rimini Italy
| | - S. Kovalchuk
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - C. Bottelli
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| | - S. Ferrero
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - D. Dessì
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - E. Cencini
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - E. Pennese
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | | | - C. Mammi
- GRADE; Gruppo Amici dell'Ematologia Foundation; Reggio Emilia Italy
| | - S. Luminari
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - A. Tucci
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| |
Collapse
|
5
|
Cox C, Castiello L, Mattei M, Santodonato L, D'agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Borgioni S, Carlei D, Monque D, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini S, Rozera C, Arico' E, Capone I, Belardelli F. INTRANODAL TREATMENT WITH IFNΑ-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.126_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Cox
- Haematology; AOU Sant'Andrea, Rome, Italy & King's College Foundation Trust; London United Kingdom
| | - L. Castiello
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - M. Mattei
- Radiology; AOU Sant'Andrea; Rome Italy
| | - L. Santodonato
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - G. D'agostino
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Muraro
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - D. Martorelli
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - C. Lapenta
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - A. Di Napoli
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Di Landro
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - M. Cangemi
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - A. Pavan
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | | | - S. Hohaus
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - S. Donati
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - E. Montefiore
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | | | | | - D. Carlei
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - D. Monque
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - L. Ruco
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - D. Prosperi
- Nuclear Medicine; AOU Sant'Andrea; Rome Italy
| | - A. Tafuri
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Spadaro
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - P. Sestili
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - M. Spada
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - R. Dolcetti
- Diamantina Institute; Translational Research Institute, The University of Queensland; Brisbane Australia
| | - S. Santini
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - C. Rozera
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Arico'
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - I. Capone
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - F. Belardelli
- institute of Translational Pharmacology; CNR; Rome Italy
| |
Collapse
|
6
|
Visco C, Di Rocco A, Tisi M, Morello L, Evangelista A, Zilioli V, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani P, Cox M, Bozzoli V, Fabbri A, Polli V, Ferrero S, De Celis I, Sica A, Arcaini L, Balzarotti M, Rule S, Vitolo U. OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.16_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. Visco
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - A. Di Rocco
- Translational and Precision Medicine; Sapienza University of Rome; Rome Italy
| | - M.C. Tisi
- Medicine, Section of Hematology; University of Verona; Verona Italy
| | - L. Morello
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - A. Evangelista
- Clinical Epidemiology; Città della Salute e della Scienza and CPO Piemonte; Torino Italy
| | - V.R. Zilioli
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - C. Rusconi
- Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - S. Hohaus
- Institute of Hematology, Policlinico Gemelli Foundation; Catholic University of the Sacred Heart; Roma Italy
| | - R. Sciarra
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - A. Re
- Hematology; Spedali Civili; Brescia Italy
| | - C. Tecchio
- Medicine, Section of Hematology and Bone Marrow Transplant; University of Verona; Verona Italy
| | - A. Chiappella
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| | - A. Marin-Niebla
- Hematology; Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Spain
| | - R. McCulloch
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - G. Gini
- Hematology, Department of Clinical and Molecular Sciences; Marche Polytechnic University; Ancona Italy
| | - T. Perrone
- Hematology; University of Bari; Bari Italy
| | - L. Nassi
- Hematology; Azienda Ospedaliero-Universitaria Maggiore della Carità; Novara Italy
| | - E. Pennese
- Hematology; UOSD "Centro Diagnosi e Terapia dei Linfomi"; PO Santo Spirito Pescara Italy
| | - P.M. Stefani
- Hematology; Ca' Foncello Hospital; Treviso Italy
| | - M.C. Cox
- Hematology; AOU Sant'Andrea; Rome Italy
| | | | - A. Fabbri
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - V. Polli
- Hematology; Ospedale degli Infermi; Rimini Italy
| | - S. Ferrero
- Molecular Biotechnologies and Health Sciences; University of Torino/AOU "Città della Salute e della Scienza di Torino"; Torino Italy
| | - I.A. De Celis
- Hematology; AUSLL/IRCCS Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - A. Sica
- Hematology; Policlinico di Napoli; Napoli Italy
| | - L. Arcaini
- Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Balzarotti
- Hematology; Humanitas Clinical and Research Center; Rozzano Italy
| | - S. Rule
- Haematology; University of Plymouth and Derriford Hospital; Plymouth United Kingdom
| | - U. Vitolo
- Hematology; Città della salute e della scienza University Hospital; Torino Italy
| |
Collapse
|
7
|
Catucci F, Chiesa S, Giraffa M, Maiolo E, Beghella F, Zinicola T, Hohaus S, Rufini V, Valentini V, Balducci M. PO-0758 Whole brain RT plus concomitant Temozolamide in PCNSL after MTX-HD: a prospective phase II study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31178-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Beghella Bartoli F, Zinicola T, Chiesa S, Catucci F, Giraffa M, Mazzarella C, Marchesano D, Dinapoli N, D’Alò F, Hohaus S, Valentini V, Balducci M. EP-1254 When could we spare hippocampus in the WB radiation for the primary central nervous system lymphoma? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31674-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Catucci F, Chiesa S, Maiolo E, Giraffa M, Beghella Bartoli F, Zinicola T, Hohaus S, Rufini M, Valentini V, Balducci M. P05.90 A prospective phase II study of whole brain radiotherapy concomitant to Temozolomide in primary central nervous system lymphoma after high dose methotrexate. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- F Catucci
- Fondazione Policlinico A. Gemelli IRCCS, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - S Chiesa
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - E Maiolo
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Ematologia, Roma, Italia, Rome, Italy
| | - M Giraffa
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - F Beghella Bartoli
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - T Zinicola
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - S Hohaus
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Ematologia, Roma, Italia, Rome, Italy
| | - M Rufini
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Medicina Nucleare, Roma, Italia, Rome, Italy
| | - V Valentini
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| | - M Balducci
- Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Roma, Italia, Rome, Italy
| |
Collapse
|
10
|
Zinicola T, Chiesa S, Beghella Bartoli F, Catucci F, Giraffa M, Marchesano D, Hohaus S, Mattiucci GC, Valentini V, Balducci M. P05.86 Hippocampal sparing in primary central nervous system lymphoma. Is it routinely possible? Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Zinicola
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - S Chiesa
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - F Beghella Bartoli
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - F Catucci
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Rome, Italy
| | - M Giraffa
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - D Marchesano
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Rome, Italy
| | - S Hohaus
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Ematologia, Rome, Italy
| | - G C Mattiucci
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - V Valentini
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| | - M Balducci
- Fondazione Policlinico A. Gemelli IRCSS - Università Cattolica del Sacro Cuore, Dipartimento Scienze Radiologiche, Radioterapiche ed Ematologiche, Istituto di Radiologia, Rome, Italy
| |
Collapse
|
11
|
Bruscaggin A, Spina V, Di Trani M, Martini M, Locatelli S, Cupelli E, Forestieri G, Condoluci A, Cuccaro A, Moccia A, Stathis A, Manzoni M, Deambrogi C, Diop F, Stüssi G, Cavalli F, Bertoni F, Zucca E, Larocca L, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_51] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Bruscaggin
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Spina
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - M. Di Trani
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - M. Martini
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - S. Locatelli
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - E. Cupelli
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Forestieri
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - A. Condoluci
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Cuccaro
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - A. Moccia
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Manzoni
- Department of Oncology and Hemato-Oncology; University of Milano; Milan Italy
| | - C. Deambrogi
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - F. Diop
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Stüssi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - E. Zucca
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L.M. Larocca
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - S. Hohaus
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - C. Carlo-Stella
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - D. Rossi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
12
|
Cuccaro A, Galli E, Visconti F, Zangrilli I, Corrente F, Bellesi S, Basile U, Annunziata S, Rufini V, Balducci M, D'Alò F, Hohaus S. 25(OH) vitamin D serum levels associate with patient characteristics and outcome in Hodgkin lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_48] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - E. Galli
- Polo Oncologico; Hematology; Rome Italy
| | | | | | | | | | - U. Basile
- Laboratory Medicine, Laboratory Medicine; Rome Italy
| | | | | | | | - F. D'Alò
- Polo Oncologico; Hematology; Rome Italy
| | - S. Hohaus
- Polo Oncologico; Hematology; Rome Italy
| |
Collapse
|
13
|
Pellegrini C, Pulsoni A, Rigacci L, Patti C, Gini G, Tani M, Rusconi C, Romano A, Vanazzi A, Hohaus S, Mazza P, Molica S, Corradini P, Gaudio F, Ronconi F, Pinto A, Pavone V, Volpetti S, Visentin A, Bonfichi M, Schiavotto C, Spina M, Carella A, Argnani L, Zinzani P. REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Pellegrini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - A. Pulsoni
- Hematology, Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Rigacci
- Hematology Department; University and Hospital Careggi; Florence Italy
| | - C. Patti
- Hematology; Azienda Ospedali Riuniti Villa Sofia Cervello; Palermo Italy
| | - G. Gini
- Hematology; Ospedali Riuniti; Ancona Italy
| | - M. Tani
- Hematology; Santa Maria delle Croci Hospital; Ravenna Italy
| | - C. Rusconi
- Division of Hematology Niguarda Cancer Center; Niguarda Hospital; Milan Italy
| | - A. Romano
- Hematology, Azienda Policlinico-OVE; University of Catania; Catania Italy
| | - A. Vanazzi
- Division of Clinical Haemato-Oncology; IEO; Milan Italy
| | - S. Hohaus
- Institute of Hematology; Catholic Unicversityof the Sacred Heart; Rome Italy
| | - P. Mazza
- Department of Hematology-Oncology; Ospedale Moscati; Taranto Italy
| | - S. Molica
- Hematology; Azienda Ospedaliera Pugliese-Ciaccio; Catanzaro Italy
| | - P. Corradini
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Gaudio
- Hematology; Policlinico di Bari; Bari Italy
| | - F. Ronconi
- Division of Hematology and Stem Cell Transplantation Unit; Cardarelli Hospital; Naples Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale, IRCCS; Naples Italy
| | - V. Pavone
- Hematology; Ospedale G. Panico; Lecce Italy
| | - S. Volpetti
- Hematology; Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padova Italy
| | - M. Bonfichi
- Hematology; IRCCS Policlinico San Matteo; Pavia Italy
| | | | - M. Spina
- Division of Medical Oncology A; National Cancer Institute; Aviano Italy
| | - A. Carella
- Division of Hematology 1; IRCCS A.O.U. San Martino IST; Genoa Italy
| | - L. Argnani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| |
Collapse
|
14
|
Tisi MC, Giustiniani MC, D'Alò F, Sica S, Hohaus S, Pagano L. A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia. Ann Hematol 2015; 95:517-8. [PMID: 26666534 DOI: 10.1007/s00277-015-2576-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Accepted: 12/04/2015] [Indexed: 11/24/2022]
Affiliation(s)
- M C Tisi
- Institute of Hematology, Catholic University S. Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy.
| | - M C Giustiniani
- Institute of Pathological Anatomy, Catholic University S. Cuore, Rome, Italy
| | - F D'Alò
- Institute of Hematology, Catholic University S. Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy
| | - S Sica
- Institute of Hematology, Catholic University S. Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy
| | - S Hohaus
- Institute of Hematology, Catholic University S. Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy
| | - L Pagano
- Institute of Hematology, Catholic University S. Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy
| |
Collapse
|
15
|
Testa AC, De Blasis I, Di Legge A, Belli P, Hohaus S, Ferrandina G. Burkitt's lymphoma of the breast metastatic to the ovary diagnosed during pregnancy. Ultrasound Obstet Gynecol 2013; 42:364-366. [PMID: 24137791 DOI: 10.1002/uog.12533] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
16
|
Bussu F, Hohaus S, Bastanza G, Bozzoli V, Tisi M, Martini M, Paludetti G, Almadori G. Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients. Clin Otolaryngol 2013; 38:248-53. [DOI: 10.1111/coa.12090] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/04/2012] [Indexed: 11/28/2022]
Affiliation(s)
- F. Bussu
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - S. Hohaus
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Bastanza
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - V. Bozzoli
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - M.C. Tisi
- Institute of Haematology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - M. Martini
- Institute of Histopatology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Paludetti
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| | - G. Almadori
- Institute of Otolaryngology; Università Cattolica del Sacro Cuore; Policlinico Agostino Gemelli; Rome; Italy
| |
Collapse
|
17
|
Figueroa M, Sotzen J, Fabiani E, Flanchi L, Hohaus S, Leone G, Voso M. P-009 Distinct epigenetic abnormalities distinguish therapy-related myeloid neoplasms (t-MN) following Hodgkin lymphoma (HL) vs. breast cancer (BC). Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70058-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Balducci M, Chiesa S, De Filippo L, Falcinelli L, Hohaus S, Ballanti S, Aristei C. PO-0657: Radiotherapy plus dose escalation temozolomide in primary central nervous system lymphoma: final report. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32963-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Voso MT, Fabiani E, Fianchi L, Falconi G, Criscuolo M, Santangelo R, Chiusolo P, Betti S, D'Alo' F, Hohaus S, De Stefano V, Leone G. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2012; 27:982-5. [PMID: 22964944 DOI: 10.1038/leu.2012.267] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
20
|
Voso M, Fianchi L, Criscuolo M, Greco M, D’Alo F, Hohaus S, Pagano L, Leone G. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. Leuk Res 2012; 36:e15-7. [DOI: 10.1016/j.leukres.2011.08.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Revised: 07/27/2011] [Accepted: 08/15/2011] [Indexed: 10/17/2022]
|
21
|
Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S, Mecucci C, Leone G. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia 2011; 25:1910-3. [PMID: 21760590 DOI: 10.1038/leu.2011.170] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
22
|
Hasan SK, Buttari F, Ottone T, Voso MT, Hohaus S, Marasco E, Mantovani V, Garagnani P, Sanz MA, Cicconi L, Bernardi G, Centonze D, Lo-Coco F. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011; 76:1059-65. [PMID: 21346221 DOI: 10.1212/wnl.0b013e318211c3c8] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Single nucleotide polymorphisms (SNPs) in double-strand break repair genes may alter DNA repair capacity and, in turn, confer predisposition to leukemia. We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ). METHODS Using MassARRAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, we genotyped patients with sAPL (n=20) developed after treatment of MS (18 out 20 treated with MTZ) for the presence of 210 SNPs of 22 genes mostly involved in DNA repair and drug detoxification. Patients with MS who did not develop sAPL including 41 treated with MTZ (n=253 and 41, respectively) and healthy blood donors (n=310) were also genotyped as controls. RESULTS We observed risk allele frequency between MS and sAPL for BRCA2 (rs1801406): 6% and 26%, p=0.007; XRCC5 (rs207906): 2.5% and 15%, p=0.016; CYP3A4 (rs2740574): 4.5% and 25%, p=0.0035. The association of homozygous variants of BRCA2 and XRCC5 yielded higher risk of sAPL (MS vs sAPL: 0.4% and 18%, p=0.001). We also observed a significant association between a SNP in the promoter region (rs2740574) of CYP3A4, an enzyme involved in the metabolism of chemotherapeutic agents and development of sAPL. CONCLUSIONS Increased susceptibility to develop sAPL in patients with MS receiving MTZ may be linked to genetic variants in DNA repair and drug-metabolizing enzymes that result in impaired detoxification of chemotherapy or inefficient repair of drug-induced genetic damage.
Collapse
Affiliation(s)
- S K Hasan
- Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Manfrida S, Chiesa S, Teofili L, Diletto B, Hohaus S, Fiorentino A, De Bari B, Frascino V, Aristei C, Balducci M. 44 High dose methotrexate followed by temozolomide plus concomitant radiation therapy in patients with newly diagnosed primary central nervous system Lymphoma: Preliminary results of a phase I dose escalation study. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70715-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
24
|
Chiesa S, De Santis M, Teofili L, Manfrida S, Vannata B, Frascino V, Fiorentino A, Calcagni L, Hohaus S, Balducci M. 115 poster: Prognostic Value of Pre-Radiotherapy FDG-PET in Advanced Hodgkin’S Disease Treated by Beacopp Chemotherapy Regimen. Radiother Oncol 2010. [DOI: 10.1016/s0167-8140(15)34534-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 2009; 20:1408-13. [PMID: 19465421 DOI: 10.1093/annonc/mdp006] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases. PATIENTS AND METHODS Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene. RESULTS Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all). Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively). In HL, histological signs of necrosis and grade 2 type of nodular sclerosis were associated with increased plasma DNA. Elevated plasma DNA levels were associated with an inferior failure-free survival in patients with HL (P = 0.01) and DLBCL (P = 0.03). CONCLUSION Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.
Collapse
Affiliation(s)
- S Hohaus
- Istituto di Ematologia e di Anatomia Patologica, Università Cattolica S. Cuore, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Voso MT, Hohaus S, Guidi F, Fabiani E, D'Alò F, Groner S, Späth D, Doehner K, Leone G, Doehner H, Schlenk RF. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008; 22:1685-91. [DOI: 10.1038/leu.2008.169] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
27
|
Voso MT, Fabiani E, D'Alo' F, Guidi F, Di Ruscio A, Sica S, Pagano L, Greco M, Hohaus S, Leone G. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007; 18:1523-8. [PMID: 17761709 DOI: 10.1093/annonc/mdm191] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Polymorphisms in genes involved in detoxification and DNA-repair pathways may modify the individual's risk for genomic damage, and, as a consequence, the risk of developing malignant diseases. PATIENTS AND METHODS We performed a case-control study including 160 cases of acute myeloid leukaemia (AML) and 162 matched controls to test the impact of six genomic polymorphisms on the risk to develop AML and/or therapy-related AML. RESULTS We found a significantly higher prevalence of the polymorphic variants RAD51-G135C and CYP3A4-A-290G genes in AML cases, when compared with controls (P = 0.02 and P = 0.04), increasing the risk of AML 2.1-folds (95% CI: 1.1-4.0) and 3.2-fold (95% CI: 1.1-11.5), respectively. Carriers of both the RAD51-G135C and CYP3A4-A-290G variants were at highest AML risk (P = 0.003; OR:13,6; 95% CI: 2.0-585.5), suggesting a synergistic effect between these polymorphisms. CONCLUSIONS These results suggest that polymorphic variants in DNA-repair and detoxification enzymes may co-operate in modulating the individual's risk of AML.
Collapse
Affiliation(s)
- M T Voso
- Istituto di Ematologia, Universita' Cattolica del Sacro Cuore, Roma, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007; 18:1376-81. [PMID: 17496310 DOI: 10.1093/annonc/mdm132] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND In Hodgkin's lymphoma (HL), the production of cytokines by Reed-Sternberg cells and the surrounding tissue is thought to contribute to the biology of the disease. Cytokine expression can be altered by common single nucleotide polymorphisms (SNPs) in the 5'-promoter regions. PATIENTS AND METHODS We studied polymorphic allele variants of the cytokine genes interleukin (IL)-10 (T-3575A, G-2849A, C-2763A, A-1082G and C-592A), IL-6 (G-174C) and tumor necrosis factor-alpha (C-863A and G-308A) in 184 patients with HL, and analyzed for associations with treatment outcome. RESULTS Carriers of the IL-10-592AA and the IL-6-174GG genotypes had a significantly lower probability of freedom from treatment failure (FFTF) with adjusted hazard ratios (HRs) for failure of 2.92 [95% CI (confidence interval) 1.58-5.41, P = 0.001] and of 1.75 (95% CI 1.04-2.92, P = 0.03), respectively. Reconstructing haplotypes from the five SNPs in the IL-10 promoter revealed that homozygous carriers of the IL-10.4 haplotype (T-G-C-A-A) had a worse FFTF (HR, 2.35; 95% CI 1.2-4.6, P = 0.01). In the Cox multivariate analysis, the IL-10-592AA, the IL-6-174GG genotypes and stage were independent prognostic factors. CONCLUSIONS Our study indicates that cytokine genotypes predict clinical outcome in patients with HL and points to the importance of the genetic background of the host for treatment response.
Collapse
Affiliation(s)
- S Hohaus
- Istituto di Ematologia e di Anatomia Patologica, Universita' Cattolica S. Cuore, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Voso M, Gumiero D, D'Alo' F, Scardocci A, Greco M, Fabiani E, Di Ruscio A, Guidi F, Rutella S, Bellesi S, Fianchi L, Hohaus S, Leone G. P025 Dap-kinase hypermethylation and apoptosis in myelodysplastic syndromes. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70095-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Voso M, Fabiani E, Scardocci A, D'Alo' F, Greco M, Di Ruscio A, Guidi F, Fianchi L, Pagano L, Hohaus S, Leone G. C002 Polymorphisms of DNA-repair and detoxification enzymes in myelodysplastic syndromes. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70040-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Giordano G, Piano S, Marra R, Iacoviello L, De Stefano V, Leone G, Hohaus S, Donati M, Storti S. PO-104 Non Hodgkin lymphoma (NHL) and deep venous thrombosis: a dangerous liaison still unexplored. Thromb Res 2007. [DOI: 10.1016/s0049-3848(07)70257-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Scardocci A, Guidi F, D'Alo' F, Gumiero D, Fabiani E, DiRuscio A, Martini M, Larocca LM, Zollino M, Hohaus S, Leone G, Voso MT. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer 2006; 95:1108-13. [PMID: 17047656 PMCID: PMC2360697 DOI: 10.1038/sj.bjc.6603392] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
BRCA1 plays a pivotal role in the repair of DNA damage, especially following chemotherapy and ionising radiation. We were interested in the regulation of BRCA1 expression in acute myeloid leukaemia (AML), in particular in therapy-related forms (t-AML). Using real-time PCR and Western blot, we found that BRCA1 mRNA was expressed at barely detectable levels by normal peripheral blood granulocytes, monocytes and lymphocytes, whereas control BM-mononuclear cells and selected CD34+ progenitor cells displayed significantly higher BRCA1 expression (P=0.0003). Acute myeloid leukaemia samples showed heterogeneous BRCA1 mRNA levels, which were lower than those of normal bone marrows (P=0.0001). We found a high frequency of hypermethylation of the BRCA1 promoter region in AML (51/133 samples, 38%), in particular in patients with karyotypic aberrations (P=0.026), and in t-AML, as compared to de novo AML (76 vs 31%, P=0.0002). Examining eight primary tumour samples from hypermethylated t-AML patients, BRCA1 was hypermethylated in three of four breast cancer samples, whereas it was unmethylated in the other four tumours. BRCA1 hypermethylation correlated to reduced BRCA1 mRNA (P=0.0004), and to increased DNA methyltransferase DNMT3A (P=0.003) expression. Our data show that reduced BRCA1 expression owing to promoter hypermethylation is frequent in t-AML and that this could contribute to secondary leukaemogenesis.
Collapse
MESH Headings
- Acute Disease
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- BRCA1 Protein/genetics
- BRCA1 Protein/metabolism
- Blotting, Western
- Cell Line, Tumor
- CpG Islands/genetics
- DNA (Cytosine-5-)-Methyltransferases/genetics
- DNA (Cytosine-5-)-Methyltransferases/metabolism
- DNA Methylation
- DNA Methyltransferase 3A
- Down-Regulation/genetics
- Drug-Related Side Effects and Adverse Reactions
- Female
- HL-60 Cells
- Humans
- Jurkat Cells
- Leukemia, Myeloid/etiology
- Leukemia, Myeloid/genetics
- Leukemia, Myeloid/metabolism
- Leukemia, Myeloid/pathology
- Male
- Middle Aged
- Neoplasms/therapy
- Promoter Regions, Genetic/genetics
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Radiotherapy/adverse effects
Collapse
Affiliation(s)
- A Scardocci
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - F Guidi
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - F D'Alo'
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - D Gumiero
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - E Fabiani
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - A DiRuscio
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - M Martini
- Anatomia Patologica e di, Universita' Cattolica Sacro Cuore, Roma, Italy
| | - L M Larocca
- Anatomia Patologica e di, Universita' Cattolica Sacro Cuore, Roma, Italy
| | - M Zollino
- Genetica Umana, Universita' Cattolica Sacro Cuore, Roma, Italy
| | - S Hohaus
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - G Leone
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
| | - M T Voso
- Istituti di Ematologia, di, Universita' Cattolica Sacro Cuore, L.go A. Gemelli, 1, 00168 Roma, Italy
- E-mail:
| |
Collapse
|
33
|
Seute A, Sinn HP, Schlenk RF, Emig R, Wallwiener D, Grischke EM, Hohaus S, Döhner H, Haas R, Bentz M. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 2001; 93:80-4. [PMID: 11391625 DOI: 10.1002/ijc.1296] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Little is known about the prognostic impact of chromosome aberrations in breast cancer. The aim of our study was to determine whether genomic aberrations of prognostic relevance can be identified in the context of a clinical study using molecular cytogenetics. Paraffin-embedded tumor samples of 44 patients with high-risk stage II/III breast cancer were analyzed by comparative genomic hybridization. All patients received identical therapy including dose-escalated chemotherapy followed by peripheral blood stem cell transplantation. The most frequent chromosomal aberrations were gains on chromosome arms 17q (24 cases), 1q (21 cases), 8q (17 cases), 20q (13 cases), 6p (9 cases) as well as losses on chromosome arms 13q (25 cases), 11q (20 cases), 5q (11 cases), 6q (11 cases), 9p (10 cases), 18q (10 cases), 8p (9 cases) and 16q (9 cases). In univariate analysis, the correlation with the clinical outcome revealed a higher risk for patients with tumors exhibiting 13q losses and a reduced risk for tumors exhibiting 16q losses (p = 0.020), 6q losses (p = 0.041) and estrogen-receptor positivity (0.051). In multivariate analysis using the Cox model, only the loss of 16q exhibited borderline significance (p = 0.065). These data show that comparative genomic hybridization can be performed in the context of a clinical trial. In our subgroup of high-risk breast cancer patients, chromosomal aberrations were valuable prognostic parameters.
Collapse
MESH Headings
- Adult
- Analysis of Variance
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Chromosome Aberrations
- Chromosome Deletion
- Chromosome Mapping
- Chromosomes, Human, Pair 1
- Chromosomes, Human, Pair 17
- Chromosomes, Human, Pair 6
- Chromosomes, Human, Pair 8
- Combined Modality Therapy
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Mastectomy
- Middle Aged
- Neoplasm Staging
- Postmenopause
- Premenopause
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
Collapse
Affiliation(s)
- A Seute
- Abt. Innere Medizin III, Universität Ulm, Ulm, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Schneeweiss A, Hensel M, Goerner R, Khbeis T, Hohaus S, Egerer G, Solomayer E, Haas R, Grischke EM, Bastert G, Ho AD. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. Stem Cells 2001; 19:151-60. [PMID: 11239170 DOI: 10.1634/stemcells.19-2-151] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy. We compared the progression-free survival (PFS) and overall survival (OS) of 20 patients treated with a double (D)-HDCT regimen to 20 patients who received a triple (T)-HDCT, matched by age, estrogen receptor (ER) status, adjuvant chemotherapy, initial disease-free interval, predominant metastatic site, and number of metastatic sites. At a median follow-up of 41.5 months (range, 14-88 months) an intent-to-treat analysis showed no difference in PFS (p = 0.72) and OS (p = 0.93) between the matched patients. For all 76 patients treated within the D- or T-HDCT trial, median PFS and OS was 13 months (range, 2-78 months) and 24.5 months (range, 7-78 months), respectively. In multivariate analysis independent predictors of shorter OS included negative ER (relative risk [RR] = 3.0 [95% confidence interval (CI) 1.5-5.9]; p = 0.002), more than two metastatic sites (RR = 2.4 [95% CI 1.0-5.7]; p = 0.049) and failure to achieve complete remission/no evidence of disease (CR/NED) after HDCT (RR = 4.5 [95% CI 2.0-10.1]; p < 0.0001). These data show that early dose intensification with T-HDCT is not superior to a D-HDCT regimen in patients with MBC. ER-negative tumors, more than two metastatic sites and no CR/NED after HDCT, are associated with inferior outcome.
Collapse
Affiliation(s)
- A Schneeweiss
- Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Neben K, Hohaus S, Goldschmidt H, Egerer G, Voso MT, Ho AD, Haas R. High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. Ann Hematol 2000; 79:547-55. [PMID: 11100744 DOI: 10.1007/s002770000190] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
From March 1986 to March 1998, 82 patients with relapsed or refractory Hodgkin's disease underwent high-dose chemotherapy (HDCT) with peripheral blood stem cell (PBSC) transplantation in our center. This is a retrospective analysis of the long-term clinical outcome. There were 52 males and 30 females with a median age of 32 years (range 18-59 years). Prior to transplantation, 36 patients were in complete remission (CR), 34 in partial remission (PR), and 12 had refractory disease after salvage therapy. For HDCT, 78 patients were treated with CBV (cyclophosphamide, 6.0-6.8 g/ m2; etoposide, 1.0-1.6 g/m2; carmustine, 0.45-0.8 g/m2), while four patients received different regimens. Probability of freedom from progression (FFP), overall survival (OS), and event-free survival (EFS) at 5 years of the entire group was 63%, 61%, and 54%, respectively. Early mortality rate ( < or = 100 days) declined from 17% to 6% after 1992. Five patients died of late transplant-related complications (> 100 days), including secondary lymphoma and leukemia in two patients. None of the refractory patients survived beyond 3.5 years. Multivariate analyses identified extranodal sites of disease at relapse and refractory disease status prior to transplantation as significant prognostic factors for FFP, EFS, and OS. As we have shown in our study, remarkable progress was achieved in reducing early morbidity and mortality over time, but this was associated with only a slight, not significant improvement of long-term outcome (OS 66% vs 57% at 5 years for patients undergoing PBSC transplantation before and after 1992, P = 0.26). Although the results as a whole are encouraging for chemosensitive patients, new therapeutic strategies are needed to reduce toxicity and improve the clinical outcome of patients, especially of those with a less favorable prognosis.
Collapse
Affiliation(s)
- K Neben
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
36
|
Nierhoff D, Horvath HC, Mytilineos J, Golling M, Bud O, Klar E, Opelz G, Voso MT, Ho AD, Haas R, Hohaus S. Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation. Blood 2000; 96:763-7. [PMID: 10887146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Lymphoid and dendritic cells of donor origin can be detected in the recipient several years after a solid organ transplantation. This phenomenon is termed microchimerism and could play a role in the induction of tolerance. The fate of other hematopoietic cells transferred by liver transplantation, in particular of stem and progenitor cells, is unknown. For this reason, we studied peripheral blood and bone marrow samples of 12 patients who had received a liver transplant from an HLA-DR mismatched donor. Eight patients were long-term survivors between 2.8 and 10.1 years after allografting. CD34(+) cells from bone marrow were highly enriched with the use of a 2-step method, and a nested polymerase chain reaction was applied to detect donor cells on the basis of allelic differences of the HLA-DRB1 gene. Rigorous controls with DRB1 specificities equal to the donor and host were included. In 5 of 8 long-term liver recipients, donor-specific CD34(+) cells could be detected in bone marrow. Microchimerism in the CD34(+) cell fraction did not correlate to the chimeric status in peripheral blood. In conclusion, our results demonstrate a frequent microchimerism among bone marrow-derived CD34(+) cells after liver transplantation. The functional role of this phenomenon still needs to be defined. (Blood. 2000;96:763-767)
Collapse
Affiliation(s)
- D Nierhoff
- Departments of Internal Medicine V and Surgery, Institute of Transplantation Immunology, University of Heidelberg, Clinical Cooperation Unit, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M, Ho AD, Haas R, Hohaus S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109:729-35. [PMID: 10929022 DOI: 10.1046/j.1365-2141.2000.02084.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We performed a pilot study including rituximab (Mabthera; IDEC-C2B8, Hoffmann-La Roche) with a sequential high-dose therapy protocol in 15 patients with follicular and three patients with mantle cell lymphoma and studied the potential of the chemoimmunotherapy to induce depletion of malignant B cells in vivo. Our treatment protocol included induction with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy, followed by peripheral blood stem cell (PBSC) mobilization using high-dose cytosine arabinoside (2 g/m2 every 12 h, days 1 and 2) and mitoxantrone (10 mg/m2, days 2 and 3) (HAM), preceeded by rituximab (375 mg/m2). The proportion of CD19+ B cells in blood and bone marrow decreased from 1.2 +/- 0.4% to 0.13 +/- 0. 1% (P = 0.01) and from 2.7 +/- 0.8% to 0.8 +/- 0.5% (P = 0.03) respectively. The number of t(14;18)-positive cells in blood and bone marrow progressively decreased with treatment, as assessed by the quantitative real-time PCR assay in four patients. Conversion to PCR-negativity was achieved in the peripheral blood (PB) of seven informative patients. Leucaphereses were performed during the granulocyte colony-stimulating factor (G-CSF)-supported leucocyte recovery phase. In 17 of 18 patients, a median of 15.1 x 106 CD34+ cells/kg body weight (BW) could be harvested by a single procedure for enrichment by an immunomagnetic method. Leucapheresis products contained 51.3 +/- 28.8 x 104 CD19+ B cells/kg BW (mean) and were t(14;18) PCR negative in all seven informative patients. These data compare favourably with results obtained in patients treated with the same regimen without rituximab. The high-dose therapy (n = 12 patients), including total body irradiation (14.4 Gy) and cyclophosphamide (200 mg/kg BW), was also preceeded by rituximab. Recovery of neutrophils to > 0.5 x 109/l and of platelets to > 20 x 109/l required a median of 13.5 and 11.5 d (range 11-24 and 9-24 d) respectively. In conclusion, the addition of the CD20 antibody to chemotherapy ensured tumour depletion in vivo and allowed the collection of PBSCs devoid of tumour cells and with conserved engraftment capability.
Collapse
Affiliation(s)
- M T Voso
- Department of Internal Medicine V, University of Heidelberg, and German Cancer Research Centre, Heidelberg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Voso MT, Martin S, Hohaus S, Abdallah A, Schlenk RF, Ho AD, Haas R. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 2000; 25:957-64. [PMID: 10800063 DOI: 10.1038/sj.bmt.1702336] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This is a report on 111 patients with advanced stage follicular lymphoma who where autografted using PBSC. Seventy patients were enrolled in first remission, whereas 41 were treated in second or higher remission. High-dose therapy consisted of total body irradiation plus cyclophosphamide in 103 patients, while eight patients received BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan). Autografts contained 8.1 +/- 0.6 x 106 CD34+ cells/kg body weight. At a median follow-up of 44.2 months from PBSCT (range 4.9-77.4 months), 93 patients are alive, with a probability of overall and relapse-free survival (RFS) of 83% and 64%, respectively. A significantly higher probability of relapse was associated with male gender, involvement of more than eight lymph node areas, extra-nodal manifestations other than bone marrow and PBSCT performed in second or higher remission. In the latter group of patients, previous radiotherapy was associated with poor prognosis. The relevance of chemosensitivity as a prognostic factor was reflected by a better RFS in patients who had achieved complete remission at the time of PBSC mobilization. In a multivariate analysis, involvement of eight or more lymph nodes and high-dose therapy performed in second or higher remission were independent prognostic factors.
Collapse
Affiliation(s)
- M T Voso
- German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
39
|
Lin YS, Zhong XY, Hohaus S, Kaul S, Haas R. Detection of tumor cells in leukapheresis products from patients with breast cancer using immunocytochemical staining method. Arch Gynecol Obstet 2000; 263:119-25. [PMID: 10763840 DOI: 10.1007/s004040050009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
We used a combination of 4 monoclonal antibodies (BM7, BM8 against MUC1, 5D3 against CK8,18,19 and HEA125 against human epithelial antigen) and a sensitive immunocytochemical staining using cytospin preparation to identify breast tumor cells in leukapheresis products (LP). This assay allowed detection of one tumor cell in 1x10(6) mononuclear cells (MC). In clinical specimens, tumor cells were detected in LP from 6 of 42 (14.3%) patients in the adjuvant treatment group, from 2 of 11 (18.2%) patients in the neoadjuvant treatment group and from 9 of 43 (20.1%) in the group of patients with metastatic disease. Tumor cell counts ranged from 0.25-5 cells in 1x10(6) normal cells per LP. The median tumor cell concentration was higher in specimens from patients with metastatic disease (median=0.96) than in specimens from patients in the adjuvant and neoadjuvant treatment groups (median=0.5 and 0.75). No significant differences between the epithelial cell positive group and the epithelial cell negative group with respect to tumor size, lymph nodes involvement, tumor grade, histological type and receptor were found. We conclude that immunocytochemical staining of cytospin preparation is a sensitive and simple method to detect and quantitate breast cancer cells in LP.
Collapse
Affiliation(s)
- Y S Lin
- Department of Internal Medicine V, University Hospital, Heidelberg
| | | | | | | | | |
Collapse
|
40
|
Hohaus S, Martin S, Schneeweiss A, Voso MT, Schlenk RF, Wallwiener D, Bastert G, Haas R. Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer. Cancer Chemother Pharmacol 1999; 44 Suppl:S13-7. [PMID: 10602904 DOI: 10.1007/s002800051110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We report on the efficacy and toxicity of a sequential high-dose therapy with peripheral blood stem cell (PBSC) support in 107 patients with high-risk stage II/III breast cancer. There were 90 patients with more than 9 tumour-positive axillary lymph nodes. An induction therapy of two cycles of ifosfamide (total dose, 7,500 mg/m(2)) and epirubicin (120 mg/m(2)) was given, and PBSC were harvested during granulocyte colony-stimulating factor (G-CSF)-supported leukocyte recovery following the second cycle. The PBSC-supported high-dose chemotherapy consisted of two cycles of ifosfamide (total dose 12,000 mg/m(2)), carboplatin (900 mg/m(2)) and epirubicin (180 mg/m(2)). Patients were autografted with a median number of 4.1 x 10(6) CD34+ cells/kg (range 1.9-26.5 x 10(6)), resulting in haematological reconstitution within approximately 2 weeks following high-dose therapy. The toxicity was moderate in general, and there was no treatment-related toxic death. Twenty-nine patients (27.1% of all patients) relapsed between 3 and 46 months following the last cycle of high-dose therapy (median 15 months). The probability of disease-free and overall survival at 3 years was 56% and 83%, respectively. A multivariate analysis showed that patients with stage II disease had a significantly better probability of disease-free survival (71%) in comparison with patients with stage III disease (30%). The probability of disease-free survival was also significantly better for patients with oestrogen receptor-positive tumours (62%) compared with patients with receptor-negative ones (40%). In conclusion, sequential high-dose chemotherapy with PBSC support can be safely administered to patients with high-risk stage II/III breast cancer. Further intensification of the therapy including the addition of non-cross-resistant drugs or immunological approaches may be envisaged for patients with stage III disease and hormone receptor-negative tumours.
Collapse
Affiliation(s)
- S Hohaus
- Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115 Heidelberg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer 1999; 79:1500-7. [PMID: 10188897 PMCID: PMC2362726 DOI: 10.1038/sj.bjc.6690239] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
We report on the efficacy and toxicity of a sequential high-dose therapy with peripheral blood stem cell (PBSC) support in 85 patients with high-risk stage II/III breast cancer. There were 71 patients with more than nine tumour-positive axillary lymph nodes. An induction therapy of two cycles of ifosfamide (total dose, 7.5 g m(-2)) and epirubicin (120 mg m(-2)) was given, and PBSC were harvested during G-CSF-supported leucocyte recovery following the second cycle. The PBSC-supported high-dose chemotherapy consisted of two cycles of ifosfamide (total dose, 12,000 mg m(-2)), carboplatin (900 mg m(-2)) and epirubicin (180 mg m(-2)). Patients were autografted with a median number of 3.7 x 10(6) CD34+ cells kg(-1) (range, 1.9-26.5 x 10(6)) resulting in haematological reconstitution within approximately 2 weeks following high-dose therapy. The toxicity was moderate in general, and there was no treatment-related toxic death. Twenty-one patients relapsed between 3 and 30 months following the last cycle of high-dose therapy (median, 11 months). The probability of disease-free and overall survival at 4 years were 60% and 83%, respectively. According to a multivariate analysis, patients with stage II disease had a significantly better probability of disease-free survival (74%) in comparison to patients with stage III disease (36%). The probability of disease-free survival was also significantly better for patients with oestrogen receptor-positive tumours (70%) compared to patients with receptor-negative ones (40%). Bone marrow samples collected from 52 patients after high-dose therapy were examined to evaluate the prognostic relevance of isolated tumour cells. The proportion of patients presenting with tumour cell-positive samples did not change in comparison to that observed before high-dose therapy (65% vs 71%), but a decrease in the incidence and concentration of tumour cells was observed over time after high-dose therapy. This finding was true for patients with relapse and for those in remission, which argues against a prognostic significance of isolated tumour cells in bone marrow. In conclusion, sequential high-dose chemotherapy with PBSC support can be safely administered to patients with high-risk stage II/III breast cancer. Further intensification of the therapy, including the addition of non-cross resistant drugs or immunological approaches such as the use of antibodies against HER-2/NEU, may be envisaged for patients with stage III disease and hormone receptor-negative tumours.
Collapse
Affiliation(s)
- S Hohaus
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Voso MT, Hohaus S, Moos M, Pförsich M, Cremer FW, Schlenk RF, Martin S, Hegenbart U, Goldschmidt H, Haas R. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol 1999; 104:382-91. [PMID: 10050723 DOI: 10.1046/j.1365-2141.1999.01171.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The efficacy of an immunomagnetic purging method and the Isolex 300 devices were assessed for selecting CD34+ cells from leukapheresis products of 29 patients with non-Hodgkin's lymphoma (NHL), 39 with multiple myeloma and 34 with breast cancer. The mean purity of the CD34+ cell population was 93.6% and the mean recovery was 67.7%. Following enzymatic cleavage by chymopapain the expression of Thy-1 and Leu-8 was significantly reduced without affecting haematological recovery. The population of selected CD34+ cells of 4/8 patients with follicular lymphoma became PCR-negative. A 2.5 log reduction of tumour cells could be achieved in four patients with multiple myeloma as shown by a quantitative PCR assay. There were no tumour cells detectable in any of the 19 CD34+ cell preparations of patients with breast cancer. In 64 patients who received 94 cycles of high-dose therapy, a mean number of 4.7x 10(6) CD34+ cells/kg were autografted. The time needed for platelet reconstitution was different when a comparison was made with 156 patients, who had received unmanipulated leukapheresis products (10 v 12 d, P = 0.006). No significant differences with regard to neutrophil recovery were noted. Five patients had a graft failure. Two of them died (on day 78 and 88 following PBSCT), and three patients were rescued with unmanipulated back-up transplants. In conclusion, the immunomagnetic selection of CD34+ cells provides autografts with reduced tumour cell content and an engraftment ability similar to that of unmanipulated autografts.
Collapse
Affiliation(s)
- M T Voso
- German Cancer Research Centre, Heidelberg
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Huober J, Schneeweiss A, Hohaus S, Wittmann G, Meyer A, Martin S, Goldschmidt H, Bastert G, Haas R, Wallwiener D. Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. J Cancer Res Clin Oncol 1999; 124:690-4. [PMID: 9879830 DOI: 10.1007/s004320050233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The purpose of this phase II study was to evaluate the therapeutic efficacy and toxicity of a tandem or triple high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (PBSCT) in patients with metastatic breast cancer (MBC) as first line chemotherapy. Conventional chemotherapy consisted of two cycles of epirubicin 120 mg/m2 and ifosfamide 7500 mg/m2 in the case of tandem HDC and one cycle of paclitaxel 135 mg/m2, epirubicin 90 mg/m2 and ifosfamide 6000 mg/m2 in the case of triple HDC. Tandem HDC was composed of two cycles of epirubicin 180 mg/m2, ifosfamide 12000 mg/m2 and carboplatin 900 mg/m2. In the case of triple HDC, paclitaxel 180 mg/m2, etoposide 1500 mg/m2 and thiotepa 600 mg/m2 was added as the third cycle. Patients with tandem HDC (n = 20) were evaluable for both survival and toxicity, and patients with triple HDC (n = 21) only for toxicity because of short-term follow-up. Both tandem and triple HDC were well tolerated and could be safely administered. Non-hematological WHO grade 3 or 4 toxicities were mucositis (8), temporary renal insufficiency (1), myocardial infarction (1), and neuropathy (1). No toxic death occurred. The Kaplan-Meier estimates for 44-months without progression and the overall survival were 12% and 38% respectively. The median survival was 22 months (95% CI: 7.4-51.7 months) and the median progression-free interval 14 months (95% CI: 5.1-43.7 months). In a population with an unfavorable prognosis, tandem HDC showed similar efficacy as to that described in other phase II studies. Triple HDC seems not to improve patient outcome compared to tandem HDC, but a long-term follow up is required.
Collapse
Affiliation(s)
- J Huober
- University of Heidelberg, Department of Gynecology and Obstetrics, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Cattani P, Hohaus S, Bellacosa A, Genuardi M, Cavallo S, Rovella V, Almadori G, Cadoni G, Galli J, Maurizi M, Fadda G, Neri G. Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma. Clin Cancer Res 1998; 4:2585-9. [PMID: 9829720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Head and neck squamous cell carcinomas (SCCs) seem to follow a multistep process of carcinogenesis in which chemical and/or viral agents are associated with specific genetic alterations. The prevalence of human papillomavirus (HPV) infection and the amplification of the cyclin D1 (CCND1) gene were evaluated in a series of 75 laryngeal SCCs by PCR with HPV consensus primers and Southern blot analysis with a CCND1-specific probe, respectively. HPV DNA was detected in 22 of 75 (29.3%) tumors, and it belonged almost exclusively to the highly oncogenic HPV-16, HPV-18, and HPV-33. CCND1 gene amplification was found in 15 of 75 (20%) tumors, and it was associated with HPV infection in a statistically significant manner (chi2 = 20.3; P < 0.001). Because the viral oncoproteins E6 and E7 from high-risk HPV types are known to promote genomic rearrangements, these findings suggest that amplification of the CCND1 gene in laryngeal SCCs may occur as a consequence of the genomic instability associated with HPV infection. In turn, amplified CCND1, either alone or in conjunction with a direct action of the viral oncoproteins E6 and E7, could lead to a perturbation of the cell cycle. This model could explain the involvement of high-risk HPV types in laryngeal carcinogenesis.
Collapse
Affiliation(s)
- P Cattani
- Institute of Microbiology, Catholic University Medical School, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998; 22:625-30. [PMID: 9818688 DOI: 10.1038/sj.bmt.1701422] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The availability of hematopoietic growth factors has greatly facilitated the mobilization and collection of peripheral blood stem cells (PBSC). It was the aim of this double-blind study to compare the PBSC-mobilizing efficacy of recombinant human G-CSF and GM-CSF when administered post-chemotherapy. Twenty-six patients with relapsed Hodgkin's disease were included in the study. Their median age was 31 years (range, 22-59) and 14 patients were males and 12 were females. Patients were pretreated with a median of eight cycles of cytotoxic chemotherapy, while 18 patients had undergone extended field irradiation. The patients received dexamethasone 24 mg days 1-7, melphalan 30 mg/m2 day 3, BCNU 60 mg/m2 day 3, etoposide 75 mg/m2 days 4-7, Ara-C 100 mg/m2 twice daily days 4-7 (Dexa-BEAM). Twelve patients were randomized to receive 5/microg/kg/day G-CSF and 14 patients to receive 5 microg/kg/day GM-CSF, both administered subcutaneously starting on day 1 after the end of Dexa-BEAM. Primary endpoints of the study were the number of CD34+ cells harvested per kg body weight on the occasion of six consecutive leukaphereses and the time needed for hematological reconstitution following autografting. Twenty-one patients completed PBSC collection, and six patients of the G-CSF group and nine of the GM-CSF group were autografted. No difference was observed with respect to the median yield of CFU-GM and CD34+ cells: 32.5 x 10(4)/kg vs 31.3 x 10(4)/kg CFU-GM, and 7.6 x 10(6)/kg vs 5.6 x 10(6)/kg CD34+ cells, for G-CSF and GM-CSF, respectively (U test, P= 0.837 and 0.696). High-dose chemotherapy consisted of cyclophosphamide 1.7 g/m2 days 1-4, BCNU 150 mg/m2 days 1-4, etoposide 400 mg/m2 days 1-4. All patients transplanted with more than 5 x 10(6) CD34+ cells/kg had a rapid platelet recovery (20 x 10(9)/l) between 6 and 11 days and neutrophil recovery (0.5 x 10(9)/1) between 9 and 16 days, while patients transplanted with less than 5 x 10(6)/kg had a delayed reconstitution, regardless of the kind of growth factor used for PBSC mobilization. In conclusion, our data indicate that in patients with Hodgkin's disease G-CSF and GM-CSF given after salvage chemotherapy appear to be not different in their ability to mobilize PBSC resulting in a similar time needed for hematological reconstitution when autografted following high-dose therapy.
Collapse
Affiliation(s)
- S Hohaus
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Martin-Murea S, Voso MT, Hohaus S, Pförsich M, Fruehauf S, Goldschmidt H, Hegenbart U, Haas R. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998; 101:582-5. [PMID: 9633905 DOI: 10.1046/j.1365-2141.1998.00730.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We report on the RmetHuG-CSF (filgrastim)-related mobilization efficiency in 120 patients with multiple myeloma who received cytotoxic chemotherapy. Three schedules of G-CSF administration starting 24h after the end of chemotherapy were used: (1) a standard dose of 300 microg/d until the completion of PBSC collection; (2) dose escalation from 300 to 600-1200 microg/d during marrow recovery; (3) 600 or 1200 microg/d starting 24 h after cytotoxic chemotherapy. As a result, the individual dose per kg bodyweight varied between 2.83 and 23.08 microg. No relationship was found between the dose of G-CSF administered and the peak level of circulating CD34+ cells or the CD34+ cell counts recorded over the entire collection period.
Collapse
Affiliation(s)
- S Martin-Murea
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Hohaus S, Wallwiener D, Martin S, Voso MT, Huober J, Fersis N, Bastert G, Haas R. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Semin Oncol 1998; 25:7-11; discussion 45-8. [PMID: 9578056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Patients with high-risk breast cancer may benefit from dose-escalated chemotherapy. We studied toxicity and therapeutic efficacy of sequential high-dose therapy consisting of two cycles of ifosfamide 12,000 mg/m2, carboplatin 900 mg/m2, and epirubicin 180 mg/m2 (ICE) with peripheral blood stem cell support. Ninety-one patients with advanced breast cancer were included. Fifty-one patients with stage II/III disease and 10 or more tumor-positive axillary lymph nodes received high-dose therapy as adjuvant treatment; the remaining 40 patients were treated for metastatic disease. Peripheral blood stem cells were collected following granulocyte colony-stimulating factor-supported induction chemotherapy. In 68 patients, induction chemotherapy included two cycles of ifosfamide 7,500 mg/m2 and epirubicin 120 mg/m2, while 23 patients received one cycle of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 135 mg/m2, ifosfamide 6,000 mg/m2, and epirubicin 90 mg/m2. One hundred ninety-two cycles of ICE were supported with a median of 3.5 x 10(6) CD34+ cells/kg body weight (range, 1.7 to 38 x 10(6) CD34+ cells/kg body weight), which resulted in rapid hematologic reconstitution with recovery times, for a median neutrophil count of 0.5 x 10(9)/L of 13 days (range, 6 to 20 days) and for a median platelet count greater than 20 x 10(9)L of 9 days (range, 5 to 24 days). Seven patients received only one cycle of ICE because of progressive disease (in two patients with metastatic disease), central nervous system toxicity (one patient), cardiac toxicity (one patient), severe enterocolitis (one patient), development of human leukocyte antigen antibodies (one patient), and wish to withdraw from the study (one patient). Seventeen patients with metastatic disease received an additional high-dose cycle consisting of the non-cross-resistant agents thiotepa 600 mg/m2, etoposide 1,500 mg/m2, and paclitaxel 165 mg/m2. In patients treated adjuvantly, the probability of disease-free survival was 64% at 47 months, which compares favorably with results of conventional treatment protocols, with a 47% event-free probability at the same time period. The probability of progression-free survival in patients with metastatic disease was 18% at 44 months. In conclusion, sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer can be administered safely and offers a potential benefit in the adjuvant setting.
Collapse
Affiliation(s)
- S Hohaus
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, Haas R. Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Cancer Res 1997; 144:27-35. [PMID: 9304704 DOI: 10.1007/978-3-642-46836-0_4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The objective of our study was to evaluate the efficacy and toxicity of a high-dose melphalan-based therapy with or without total body irradiation (TBI) followed by peripheral blood progenitor cell (PBPC) transplantation in patients with multiple myeloma. Between June 1992 and June 1996, 104 patients (71 male, 33 female) with a median age of 51 years (range 30-65 years) underwent transplantation at our center. PBPC were mobilized using high-dose chemotherapy followed by treatment with G-CSF. Fifty patients were treated with TBI+melphalan 140 mg/m2 while 54 patients received melphalan 200 mg/m2. Following PBPC autografting, the median time to attainment of platelets > or = 20 x 10(9)/l and neutrophils > or = 0.5 x 10(9)/l was 11 and 14 days, with no difference between the treatment groups. In the TBI group significantly longer periods of total parenteral nutrition were required due to the occurrence of severe mucositis. Two patients from the TBI group died of transplantation-related complications. Following high-dose treatment, remission state improved in 43 out of 102 patients. No statistically significant advantage in reaching complete or partial remission was observed with TBI+high-dose melphalan compared to the treatment with high-dose melphalan alone. The optimal high-dose treatment, with particular reference to the inclusion or omission of TBI, should be prospectively investigated.
Collapse
Affiliation(s)
- H Goldschmidt
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
49
|
Hohaus S, Murea S, Voso MT, Haas R. Mobilization and selection of CD34+ cells. Recent Results Cancer Res 1997; 144:1-7. [PMID: 9304701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- S Hohaus
- Department of Internal Medicine V, University of Heidelberg, Germany
| | | | | | | |
Collapse
|
50
|
Fersis N, Haas R, Wallwiener D, Hohaus S, Huober J, Bastert G. High-dose therapy with peripheral blood progenitor cell support (PBPC) for the treatment of advanced breast cancer. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85241-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|